Member Info for jackdaw99

I think all my previous comments show that I would agree with you....

Worth probably 20p with FDA approval but without any more products ... but others ARE in the pipeline or ready for spinoff ... so 30p????

Makes a lot of sense but if an Institution REALLY wanted in, do you not think RENE would simply issue new shares, unpopular with ourselves though that may be??

Several bits all in one there: if I was in charge of PR I think I would have used to to generate three RNSs over this week!

Yes. I know some commentators assess that Novartis could easily leave OXB in the lurch and change viral suppliers, so that our position is still weak & wobbly, but I suspect that underestimates the massive OXB expertise and experience that has been devoted to this transfection operation. I doubt that Novartis, if they get approval, would want to jeopardise what could be an incredibly successful pipeline, continuing for decades, by going out on a knife-edge like that. They have the cash, and perhaps even more very soon, so why not just buy us up and bring it in house? Rumours are that some big holders would hold out for 25 pence minimum, which doesn't seem unrealistic IMO.

"I'm still taken by the theory proposed by someone else on this chat a few months back that the off-loading of OXB's pre-clinical assets earlier in the year streamlined the business and was a precursor to a bid from Novartis." I think that was me too, so it's probably still a minority thought....

Come on Zwartkops, learn to talk shit like the rest of them. "Cus thats gud"

...controlled rise, it appears, until Novartis gain approval, by which time we may be 7-8 pence? But then what?

Yes. Looks like some had advance warning yesterday.

Lots of potential now this medical imaging co gets off the ground. This is a sample of what they do in their novel diagnosis of COPD: http://posterng.netkey.at/esr/viewing/index.php?module=viewing_posteraction&task=downloadpdf&pi=132622. .... and extract from conclusions of above presentation: "HP 129Xe-MRI is non-invasive, exposes the patient to no radiation and may be performed repeatedly, potentially immediately after LVRT to determine its efficacy. This may allow early treatment modifications or allow clinicians to inform patients of the likely success of their intervention."

I'm pretty sure you need board approval for buyback so you would see it in the minutes if you searched?

This is really interesting science with massive potential but it's a hell of a long way from commercialisation. So, while it's great to have an innovative pipeline, what I think the share price needs is some near-time promise in the shape of the better-developed stem cell theraputics. Until then we will languish. I hold lots of these BTW and, on a 3-5 year view, think they will be very worth while, but there are many rivers to cross as yet.

But then they set the autos on it!

Moving' On Up!

.. shares are moving from small hands to large.

Might not have been the best timing ....

Well, the boss is a clever guy, so the latter is entirely possible. If it all works to plan you could see this tiny outfit being quickly assimilated by one of the big synthesis-houses, Bayer for example?

It seems so.

Not so much a "review", more of a clickbait, that. Absolute crap.

.. and better!